Clinical Trials of Liposomes in Children’s Anticancer Therapy: A Comprehensive Analysis of Trials Registered on ClinicalTrials.gov

References

• Jiang X, Zheng Y-W, Bao S, et al. Drug discovery and formulation development for acute pancreatitis. Drug Deliv. 2020;27(1):1562–1580. doi:10.1080/10717544.2020.1840665
   PubMed Web of Science ®Google Scholar
• Guo S, Liang Y, Liu L, et al. Research on the fate of polymeric nanoparticles in the process of the intestinal absorption based on model nanoparticles with various characteristics: size, surface charge and pro-hydrophobics. J Nanobiotechnol. 2021;19(1):32. doi:10.1186/s12951-021-00770-2
   PubMed Web of Science ®Google Scholar
• Qi -S-S, Sun J-H, Yu H-H, Yu S-Q. Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. Drug Deliv. 2017;24(1):1909–1926. doi:10.1080/10717544.2017.1410256
   PubMed Web of Science ®Google Scholar
• Kim K, Khang D. Past, present, and future of anticancer nanomedicine. Int J Nanomedicine. 2020;15:5719–5743. doi:10.2147/IJN.S254774
   PubMed Web of Science ®Google Scholar
• Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5(1):25–44. doi:10.1517/17425247.5.1.25
   PubMed Web of Science ®Google Scholar
• Suntres ZE. Liposomal antioxidants for protection against oxidant-induced damage. J Toxicol. 2011;2011:152474. doi:10.1155/2011/152474
   PubMedGoogle Scholar
• Landi-Librandi AP, Chrysostomo TN, Caleiro Seixas Azzolini AE, Marzocchi-Machado CM, de Oliveira CA, Lucisano-Valim YM. Study of quercetin-loaded liposomes as potential drug carriers: in vitro evaluation of human complement activation. J Liposome Res. 2012;22(2):89–99. doi:10.3109/08982104.2011.615321
   PubMed Web of Science ®Google Scholar
• Mignet N, Seguin J, Chabot GG. Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics. 2013;5(3):457–471. doi:10.3390/pharmaceutics5030457
   PubMedGoogle Scholar
• Feizabadi M, Fahimnia F, Mosavi Jarrahi A, Naghshineh N, Tofighi S. Iranian clinical trials: an analysis of registered trials in International Clinical Trial Registry Platform (ICTRP). J Evid Based Med. 2017;10(2):91–96. doi:10.1111/jebm.12248
   PubMedGoogle Scholar
• Chen L, Su Y, Quan L, Zhang Y, Du L. Clinical trials focusing on drug control and prevention of ventilator-associated pneumonia: a comprehensive analysis of trials registered on ClinicalTrials.gov. Original research. Front Pharmacol. 2019;9. doi:10.3389/fphar.2018.01574
   Web of Science ®Google Scholar
• Jacobsen PB, Wells KJ, Meade CD, et al. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012;30(20):2516–2521. doi:10.1200/JCO.2011.39.5186
   PubMed Web of Science ®Google Scholar
• Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DAB. Issues in the registration of clinical trials. JAMA. 2007;297(19):2112–2120. doi:10.1001/jama.297.19.2112
   PubMed Web of Science ®Google Scholar
• Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. Chest. 2009;136(1):295–303. doi:10.1378/chest.08-3022
   PubMed Web of Science ®Google Scholar
• Bai F, Yin Y, Chen T, et al. Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer. Int J Nanomedicine. 2018;13:1327–1339. doi:10.2147/IJN.S150237
   PubMed Web of Science ®Google Scholar
• Riaz MK, Riaz MA, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci. 2018;19(1):195. doi:10.3390/ijms19010195
   PubMed Web of Science ®Google Scholar
• Yue P-J, He L, Qiu SW, et al. OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma. Mol Cancer. 2014;13:191. doi:10.1186/1476-4598-13-191
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157. doi:10.1016/j.jconrel.2014.12.030
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi:10.1186/1556-276x-8-102
   PubMed Web of Science ®Google Scholar
• Al-Amin MD, Bellato F, Mastrotto F, et al. Dexamethasone loaded liposomes by thin-film hydration and microfluidic procedures: formulation challenges. Int J Mol Sci. 2020;21(5):1611. doi:10.3390/ijms21051611
   PubMed Web of Science ®Google Scholar
• Cunningham-Erves J, Deakings J, Mayo-Gamble T, Kelly-Taylor K, Miller ST. Factors influencing parental trust in medical researchers for child and adolescent patients’ clinical trial participation. Psychol Health Med. 2019;24(6):691–702. doi:10.1080/13548506.2019.1566623
   PubMed Web of Science ®Google Scholar
• Rentea RM, Oyetunji TA, Peter SDS. Ethics of randomized trials in pediatric surgery. Pediatr Surg Int. 2020;36(8):865–867. doi:10.1007/s00383-020-04665-5
   PubMed Web of Science ®Google Scholar
• Nicholl A, Evelegh K, Deering KE, et al. Using a Respectful Approach to Child-centred Healthcare (ReACH) in a paediatric clinical trial: a feasibility study. PLoS One. 2020;15(11):e0241764. doi:10.1371/journal.pone.0241764
   PubMed Web of Science ®Google Scholar
• Nik ME, Malaekeh-Nikouei B, Amin M, et al. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma. Sci Rep. 2019;9(1):9527. doi:10.1038/s41598-019-45974-7
   PubMed Web of Science ®Google Scholar
• Laverman P, Boerman OC, Storm G, Oyen WJG. (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx) in glioblastomas and metastatic brain tumours. Br J Cancer. 2002;86(4):659–661. doi:10.1038/sj.bjc.6600093
   PubMed Web of Science ®Google Scholar
• Wang G, Wang J, Wu W, Tony To SS, Zhao H, Wang J. Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert Opin Drug Deliv. 2015;12(9):1475–1499. doi:10.1517/17425247.2015.1021681
   PubMed Web of Science ®Google Scholar
• Chen EC, Fathi AT, Brunner AM. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther. 2018;11:3425–3434. doi:10.2147/OTT.S141212
   PubMed Web of Science ®Google Scholar
• Preisler HD, Anderson K, Rai K, et al. The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol. 1989;71(2):189–194. doi:10.1111/j.1365-2141.1989.tb04253.x
   PubMed Web of Science ®Google Scholar
• Zwierzyna M, Davies M, Hingorani AD, Hunter J. Clinical trial design and dissemination: comprehensive analysis of ClinicalTrials.gov and PubMed data since 2005. BMJ. 2018;361:k2130. doi:10.1136/bmj.k2130
   PubMed Web of Science ®Google Scholar
• Zhang C, Kwong JSW, Yuan R-X, et al. Effectiveness and tolerability of different recommended doses of PPIs and H(2)RAs in GERD: network meta-analysis and GRADE system. Sci Rep. 2017;7:41021. doi:10.1038/srep41021
   PubMed Web of Science ®Google Scholar
• Oh ES, Fong TG, Hshieh TT, Inouye SK. Delirium in older persons: advances in diagnosis and treatment. JAMA. 2017;318(12):1161–1174. doi:10.1001/jama.2017.12067
   PubMed Web of Science ®Google Scholar
• Italiano A, Nanda S, Briggs A, et al. Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: an intra-patient comparative analysis. Cancers. 2020;12(11):3246. doi:10.3390/cancers12113246
   PubMed Web of Science ®Google Scholar
• Dutton P, Love S, Faleti A, Hassan B. The use of Bayesian design in two trials in rare cancers. Trials. 2015;16(Suppl 2):P213. doi:10.1186/1745-6215-16-S2-P213
   PubMed Web of Science ®Google Scholar
• Blagden SP, Billingham L, Brown LC, et al. Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement. Br J Cancer. 2020;122(4):473–482. doi:10.1038/s41416-019-0653-9
   PubMed Web of Science ®Google Scholar
• Sydes MR, Parmar MKB, Mason MD, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168. doi:10.1186/1745-6215-13-168
   PubMed Web of Science ®Google Scholar
• Hearn J, Keat N, Law K, Sharpe R. How cancer research UK is adapting to adaptive designs. Trials. 2011;12(Suppl 1):A6. doi:10.1186/1745-6215-12-S1-A6
   PubMedGoogle Scholar